November 4, 2026

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Press Release on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the second quarter ended September 30, 2026

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.11.04 19:41:13 +05'30'

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India

AUROBINDO

Press Release

Hyderabad, India, November 4th, 2026: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended September 30, 2026.

Aurobindo Pharma Limited Q2FY27

Amount (INR Cr)	Q2FY27	Q2FY26	% Change YoY	Q1FY27	% Change QoQ
Revenue from Operations	10,263	8,286	23.9%	9,150	12.2%
EBITDA (Before Forex and Other Income)	2,156	1,678	28.5%	1,881	14.6%
EBITDA Margin (%)	21.0%	20.3%	75 bps	20.6%	45 bps
PBT before share of P/L of JV	1,691	1,274	32.7%	1,517	11.5%
Net Profit for the period	1,124	848	32.5%	1,032	8.9%

Key Highlights of Q2FY27

- Highest ever quarterly Revenue from Operations of INR 10,263 Cr, reporting an increase of 24% YoY, driven by growth across businesses
- US revenue increased by 25% YoY to INR 4,555 Cr (USD 477 million)
- Europe revenue increased by 27% YoY to INR 3,161 Cr (EUR 288 million)
- Growth Markets revenue increased by 16% YoY to INR 1,026 Cr (USD 107 million)
- ARV revenue for the quarter stood at INR 359 Cr (USD 38 million)
- Received final approval for 12 products from USFDA
- R&D expenditure for the quarter stood at INR 376 Cr against INR 344 Cr in the previous quarter
- Net Profit for the quarter stood at INR 1,124 Cr
- Generated strong free cash flows of USD 146 million during the quarter after accounting for strategic capex investments
- Strong net cash position (including investments) of USD 189 million as on 30-Sep-26
- Basic and Diluted EPS stood at INR 19.57 per share
- Declared an interim dividend of ₹ 7.0 per share

AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India


Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: *"We are pleased to deliver a strong performance in Q2, reflecting the strength of our business fundamentals, sustained execution and the resilience of our diversified product portfolio. Our growth is supported by healthy organic momentum across our key businesses and the successful integration of inorganic opportunities, further strengthening our capabilities and positioning us for the future. As we advance our strategic priorities, we remain focused on sustainable growth, financial discipline and creating long-term value for our stakeholders, while continuing to expand access to quality and affordable healthcare worldwide."*


Operational Performance (Consolidated)

₹ Cr	Q2FY27	Q2FY26	YoY (%)	Q1FY27	QoQ (%)
USA	4,555	3,638	25.2%	3,770	20.8%
Europe	3,161	2,480	27.5%	2,937	7.6%
Growth Markets	1,026	882	16.3%	1,063	-3.5%
ARV	359	325	10.2%	330	8.7%
Total Formulations	**9,102**	**7,325**	**24.2%**	**8,101**	**12.4%**
Beta-lactam	858	687	24.8%	800	7.3%
Non Beta-lactam	304	273	11.3%	250	21.7%
Total API	**1,162**	**961**	**20.9%**	**1,049**	**10.7%**
Revenue from Operations	**10,263**	**8,286**	**23.9%**	**9,150**	**12.2%**

Q2FY27: Consolidated Revenue Breakup - Geography & Business Wise

Q2FY27





Q2FY27: Business Wise Performance

Formulations revenue increased by 24% YoY to INR 9,102 Cr.

US Formulations

- US revenue increased by 25% YoY to INR 4,555 Cr primarily driven by successful integration, base business growth and new launches
- As on 30-Sep-26, on a cumulative basis, the company filed 900 ANDAs with USFDA and received 747 final approvals and 35 tentative approvals
- Launched 10 products in the US market (including gAdvair and ADQUEY™ our first NCE)

Europe Formulations

- Europe revenue increased by 27% YoY to INR 3,161 Cr, driven by robust performance across all key markets; and accounted for 31% of consolidated revenue
- In euro terms, revenue increased by 18% YoY to EUR 288 million

Growth Markets Formulations

- Growth Markets formulations revenue increased by 16% YoY to INR 1,026 Cr, driven by strong performance across key markets; and accounted for 10% of consolidated revenue
- In USD terms, revenue increased by 6% YoY to USD 107 million

ARV Formulations

- ARV business revenue remained broadly stable at INR 359 Cr with QoQ variation driven by tender opportunities, accounting for 3% of consolidated revenue
- In USD terms, revenue increased by 7% QoQ to USD 38 million

Active Pharmaceutical Ingredients (API)

- API revenues increased 21% YoY to INR 1,162 Cr, driven by favorable business mix and contributed 11% of consolidated revenue
- In USD terms, revenue increased by 11% YoY to USD 122 million

AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India

Q2FY27: Final USFDA Approvals Received

Aurobindo Pharma Limited

#	Product	Strength	Therapy Area
1	Sacubitril and Valsartan Tablets (FTF)	24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg	CARDIO VASCULAR
2	Etodolac Tablets USP	400 mg and 500 mg	NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)
3	Bupropion Hydrochloride Extended-Release Tablets USP	150 mg and 300 mg	CENTRAL NERVOUS SYSTEM
4	Vancomycin Hydrochloride for Oral Solution USP	25 mg/mL and 50 mg/mL	ANTI-INFECTIVE
5	Triamcinolone Acetonide Nasal Spray USP (OTC)	55 mcg per spray	RESPIRATORY DRUGS
6	Metronidazole Vaginal Gel	0.75%	ANTI-INFECTIVE
7	Adapalene and Benzoyl Peroxide Topical Gel	0.3%/2.5%	ANTI-INFECTIVE
8	Cyclosporine Capsules USP (Modified) (Soft Gelatin Capsules)	25 mg, 50 mg and 100 mg	IMMUNOSUPPRESSIVE AGENTS
9	Isotretinoin Capsules USP	20 mg, 30 mg and 40 mg	ANTI-INFECTIVE
10	Brivaracetam Oral Solution	10 mg/ mL	CENTRAL NERVOUS SYSTEM
11	Beclomethasone Dipropionate HFA, Inhalation Aerosol	40 mcg and 80 mcg	CORTICOSTEROID
12	Eslicarbazepine Acetate Tablets^^	200 mg, 400 mg, 600 mg and 800 mg	CENTRAL NERVOUS SYSTEM

^^ Received Tentative approval earlier; now received Final approval

Q2FY27: Earnings Call Details

The company will host earnings call at **8.30 AM IST on 05-Nov-26**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: https://bit.ly/4yDZFGo

AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 30+ manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

For further information, please contact:

Investor Relations | Corporate Communications
Phone: 040-66721211
Email: ir@aurobindo.com

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.11.04 19:41:39 +05'30'